Nasal moisturizers
This article was originally published in The Tan Sheet
Executive Summary
Nasal moisturizers should be removed from FDA's OTC product review and regulated as cosmetics, law firm Kirkpatrick & Lockhart (Washington, D.C.) maintains in comments to FDA. Claims that the products provide moisture for inflamed nasal membranes due to colds "is not indicating a treatment for the cold, or other specific disease, nor is it claiming to mitigate or cure that disease," lawyers assert. The comments were submitted in response to FDA's call for data on unreviewed drug products as part of the OTC safety review (1"The Tan Sheet" Jan. 5, 2004, p. 11)...
You may also be interested in...
FDA Issues Call For Data On Unreviewed OTCs To Complete Drug Review
FDA is requesting information on whether urinary analgesic/antiseptic products are appropriate for self-medication in a call for data on a range of products eligible for the OTC drug review. The notice was published in the Federal Register Dec. 31
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.